Brain cancer vaccine
A medical team of the subsidiary hospital of the Chinese Medical University on Taiwan has been developing a “brain cancer vaccine” using dendritic cells of the cancer patient, increasing the patient’s two-year survival rate from 26% to 43%.
The team reported that dendritic cells taken from the surrounding areas of the brain tumor and the actual tumor cells were grown in the same culture. The dendritic cells in the culture were then activated and “trained” to recognize the destroy the cancer cells. Then the “trained” dendritic cells that now carry the “memory” were injected into the patient, and these dendritic cells stimulated an anti-cancer immune response.
The report said that the two-year survival rate of 27 clinical brain cancer patients reached 43%.